Tango Therapeutics Inc. has provided an update on its clinical pipeline targeting multiple high-value cancer indications. The company highlighted vopimetostat as a potentially best-in-class PRMT5 inhibitor, with clinical data supporting its use in various MTAP-deleted cancers, including pancreatic and lung cancer. Tango is preparing to launch a pivotal study of vopimetostat in second-line MTAP-deleted pancreatic cancer and has initiated combination studies with RAS inhibitors for MTAP-deleted/RAS-mutant pancreatic and lung cancers. Additional pipeline advancements include a brain-penetrant PRMT5 inhibitor, TNG456, in phase 1/2 development for glioblastoma, and TNG961, which is IND-ready for multiple MTAP-deleted/FOCAD-deleted solid tumors. The company reported a cash balance of $343 million as of December 31, 2025, with a projected runway into 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.